Global Clinical Trial Patient Recruitment Services Market Analysis Sample Report

Global Clinical Trial
Patient Recruitment
Services
A sample report on
www.insights10.com
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)

This report presents a strategic analysis of the Global Clinical Trial
Patient Recruitment Services Market and a forecast for its
development in the medium and long term. It provides a comprehensive
overview of the market value, dynamics, segmentation, main players,
growth and demand drivers, challenges & future outlook, etc. This is one of
the most comprehensive reports about the Global Clinical Trial Patient
Recruitment Services Market, and offers unmatched value, accuracy,
and expert insights

3
A Sample Report on Global Clinical Trial Patient Recruitment Services Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in GlobalD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Global Clinical Trial Patient Recruitment Services Market Overview 12-25
1.1. Overview
1.2. Global Overview
1.3. Economic Overview: Global
1.4. Clinical Trial Patient Recruitment Services Market in Global
1.5. Healthcare Scenario in Global
1.6. Health Insurance Coverage: Global
1.7. Budget of the Government for Public Insurance
1.8. Mergers and Acquisitions
2. Market Size and Forecasting 26-30
2.1 Market size and forecasts (Excel and Methodology)

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
2.2.1. Market Segment 1
3. Market Dynamics 31-34
3.1. Market Growth Drivers
3.1.1. Global Clinical Trial Patient Recruitment Services Market Driver 1
3.2. Market Restraints
3.2.1. Global Clinical Trial Patient Recruitment Services Market Restraint 1

6
Table of Content
CONTENT PG. NO.
4. Competitive Landscape 35-45
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. IQVIA
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. AutoCruitment
4.2.2.1. Overview

7
Table of Content
CONTENT PG. NO.
4.2.3. Antidote
4.2.3.1. Overview
4.2.4. BBK Worldwide
4.2.4.1. Overview

8
Table of Content
CONTENT PG. NO.
4.2.5. CSSi
4.2.5.1. Overview
4.2.6. Elligo Health Research
4.2.6.1. Overview

9
Table of Content
CONTENT PG. NO.
4.2.7. Praxis
4.2.7.1. Overview
4.2.8. Science37
4.2.8.1. Overview

10
Table of Content
CONTENT PG. NO.
4.2.9. Trialspark
4.2.9.1. Overview
4.2.10. TrialX
4.2.10.1. Overview

11
Table of Content
CONTENT PG. NO.
5. Reimbursement Scenario 46-53
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis
5.3. Reimbursement Process for Treatment
5.4 Reimbursement Process – Medicare
5.5 Reimbursement Process - Medicaid
6. Methodology & Scope 54

Global Clinical Trial Patient Recruitment Services Market Analysis
1. Global Clinical Trial Patient Recruitment Services Market Overview

13
1.1 Statistics at a Glance: The Scenario of Global Clinical Trial Patient
Recruitment Services Market in the World
Scope of Global Clinical Trial Patient
Recruitment Services Market ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
$779.5 Mn
In 2022, the market for
clinical trial patient
recruiting services had
been predicted to be
worth $779.5 Mn
$1.3 Mn
Budgets for clinical trial funders have
significantly increased, as have the costs
associated with delays. If a clinical trial is
delayed because of problems with
recruitment, they could lose up to $1.3
Mn every day
32%
The most expensive part of
clinical trials is patient
recruitment, which accounts
for 32% of overall costs
50.4%
With the greatest revenue
share of 50.4% in 2021,
North America dominated
the world market

14
1.1 Statistics at a Glance: The Burden of Global Clinical Trial Patient
Recruitment Services Market in the World (continued)
North America
~ Market Size of
$xx Bn
Europe
~Revenue to reach
$xx Bn by 2027
Asia
-Fastest CAGR
Africa
~Market Size of $xx
Illustrative

15
1.2 Global Overview
7.97 Bn
Is the Global
population, in 2023
30
Is the median age
in Global, in 2022
94.69Tn
Is the Gross
Domestic Product
(GDP) in Global in
2021
$10 Tn
Public and private
healthcare spending is
anticipated to reach
over $10 trillion
globally by 2024.
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest

16
1.3 Economic Overview: Global
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Global, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Global, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

17
1.4 Global Healthcare Services
xx xx xx xx xx xx xx xx xx
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Global Healthcare Services Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Clinical Trial Patient Recruitment Services market in Global, which includes the
market size, current trends and other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
subject matter of interest
Illustrative

18
1.5 Healthcare Scenario in World
Clinical Trials Development Process: The process of developing a Clinical Trials is complex and involves many stages, from preclinical
research to clinical trials to regulatory approval. Here is a simplified diagram of the Clinical Trials development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating Clinical Trials
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for Globale in the Global market
Fast Track
▪ Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serioGlobal conditions and fill an unmet medical need
Breakthrough
Therapy
▪ A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
▪ These regulations allowed drugs for serioGlobal conditions that filled an unmet medical need to be
approved based on a surrogate endpoint
Priority Review ▪ A Priority Review designation means FDA’s goal is to take action on an application within 6 months
FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
Illustrative

19
1.6 Healthcare Scenario: Patient Journey
Presentation Diagnosis Treatment Follow up
A sGlobalpected diagnosis is
Globalually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfGlobalions,
HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron statGlobal,
liver and renal function tests,
urinalysis, LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

20
1.7 Health Insurance Coverage: Global
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care
(1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Medicare 58,541 60,226 0.5
Medicaid 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

21
1.8 Budget of Global Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Medicaid $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Medicaid 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the hoGlobaleholds (27%). The private bGlobaliness share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

22
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

23
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Oracle acquisition of
Cerner
Acquisition $28.3 Bn June, 2022
▪ Oracle’s acquisition of Cerner is big tech’s latest foray into the
healthcare system, promising better outcomes
▪ Oracle acquire Cerner through an all-cash tender offer for $95.00
per share, or approximately $28.3 Bn in equity value
▪ Cerner is a leading provider of digital information systems
Globaled within hospitals and health systems to enable medical
professionals to deliver better healthcare to individual patients
and communities
GSK acquisition of
BELLGlobal Health
Acquisition $2 Bn April 2023
▪ GSK has acquire BELLGlobal for Global$14.75 per share of
common stock in cash representing an approximate total equity
value of Global$2.0 billion
▪ BELLGlobal is a late-stage biopharmaceutical company working
to better the lives of patients suffering from persistent cough
▪ Acquisition further strengthens specialty medicines and
respiratory pipeline with camlipixant, a highly selective P2X3
antagonist and potential best-in-class treatment for refractory
chronic cough
Latest Deals In Global
Illustrative

24
1.9 Mergers and Acquisitions(continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Merger March 2023
Merger Jan 2023
Latest Deals In Global
Illustrative

2. Market Size and Forecasting

26
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Global Clinical Trials Patient Recruitment Services Market Forecast,
2022-2030 (in $Bn)
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
and other details related to the topic
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Global Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Global Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Global Market Size (Bn $) 61 74 84 87 91 95 99 106
Illustrative

27
2.2 Snapshot of Global Clinical Trial Patient Recruitment Services Market
Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Global Clinical Trial Patient Recruitment
Services Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Service Type
Patient
Recruitment &
Registry Services
Patient Retention
Services
Trial Phases
Phase I
Phase II
Phase III
Phase IV
Therapeutics
Areas
Respiratory
Diseases
Pain and
Anaesthesia
Oncology
Central Nervous
System
Cardiovascular
Age Group
Child (Birth-17
Years)
Adult (18 - 64
Years)
Older Adults (65
Years+)
Region
APAC
North America
Europe
Africa
Middle East

28
Global Clinical Trials Patient Recruitment Services Market Share,
By Service Type (2022)
Patient Retention
Services
Patient
Recruitment &
Registry
Services
▪ Patient Retention services market in
Global is a significant component of the
overall Clinical Trials treatment market
▪ It has the maximum market share in
Global Clinical Trials market with
approximately xx%
final report
2.2.1 Market Segmentation: By Service Type

29
By Trial Phases (2022)
Phase I
Phase II
Phase III
Phase IV
2.2.2 Market Segmentation: By Trial Phases
▪ Phase I market in Global is a significant
component of the overall Clinical Trials
market
approximately XX%
final report

30
Therapeutics Areas
(2022)
Respiratory
Diseases
Pain and
Anaesthesia
Oncology
Central Nervous
System
Cardiovascular
2.2.3 Market Segmentation: By Therapeutics Areas
▪ Respiratory Diseases Market have the
maximum market share in Global
Clinical Trials market with
approximately xx%
final report

31
By Age Group (2022)
Child Birth
Adult
Older Adult
2.2.4 Market Segmentation: By Age Group
▪ Child Birth market in Global is a
significant component of the overall
Clinical Trials market
approximately XX%
final report

32
By Region
(2022)
APAC
North America
Europe
Africa
Middle East
2.2.5 Market Segmentation: By Region
▪ APAC Market have the maximum
market share in Global Clinical Trials
market with approximately xx%
final report

3. Market Dynamics

34
3.1 Market growth drivers
▪ The growing need to develop new treatments for diseases and the rise in
the number of clinical trials being conducted globally are driving the
demand for patient recruitment services.
▪ This is driving the demand for Clinical Trials and creating opportunities for
growth in the Clinical Trials market
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
3.1.1 More than 30% of clinical trials were registered in the US by February 2023, and it is projected that as a result of
the considerable growth in clinical trials worldwide, which will ultimately lead to market expansion
Clinical Trials in Global

35
3.1 Market growth drivers (continued)
Top countries that are leveraging
technology in their fight against Clinical
Trials
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
3.1.2 The cancer category had the biggest revenue share in 2021, with about 34.68%. The demand for drugs has
accelerated due to the rise in cancer prevalence. Thus, this feature raises the need for clinical trials and, as a result,
helps the market grow
▪ Global has a long history of investing in Clinical Trials
research
▪ .The demand for medications and therapies to treat and
manage the disease has increased as cancer is becoming
more common.
▪ As a result of efforts by researchers and pharmaceutical
corporations to create novel and efficient therapies, the need
for clinical trials has increased.
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

36
3.2 Market restraints
3.2.1 Insufficient
enrollment causes the
termination of 34.68% of
clinical trials before
testing ever starts
▪ Inadequate enrolment can cause
delays in the trial's execution or,
in some situations, the trial's
discontinuation if an insufficient
number of participants is
enlisted.
▪ Enrollment challenges may be
caused by elements like
stringent qualifying requirements,
low participant awareness,
geographical restrictions, and
other practical problems.
3.2.2 84.68% of Clinical
Trials fail to enroll adequate
patients because of low
patient awareness and
participation
▪ Recruitment attempts may be
hampered by patients' lack of
knowledge about clinical trials
and their potential advantages
▪ Many people can be unaware of
the chance to take part in clinical
trials or they might have
preconceived notions about the
procedure and hazards involved.
▪ Finding qualified and
enthusiastic participants could
become challenging as a result.
3.2.3 Demand for Clinical Trials
care is expected to increase by
62.58% by 2035, while the supply
is only expected to increase by
29.68%
▪ There is a shortage of Clinical
Trials in Global
▪ which can limit access to Clinical
Trials
▪ and create barriers to growth in
the Clinical Trials patient
recruitment services market
Our analysis will thoroughly investigate the key restraints that may significantly impact bGlobaliness
operations and growth.

4. Competitive Landscape

38
4.1 Major Market Share
XX
Other
▪ Global Clinical Trials market is a highly
competitive space, with many companies
developing and marketing Clinical Trials
treatments
▪ Some of the top companies in Global
Clinical Trials market based on revenue
and market share include
▪ IQVIA is a Swiss multinational healthcare
company that develops and markets
Clinical Trials treatments, including
targeted therapies and immunotherapies
▪ In 2020, IQVIA's oncology sales were
approximately $24 Bn, making it one of the
largest players in Global Clinical Trials
market
Revenue of Major players in Global Clinical Trials
Patient Recruitment Services Market ($ Mn)
Illustrative

39
4.2 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let Global know via email
1 IQVIA
3 Antidote
5 CSSi
7 Praxis
9 TrialSpark
2 AutoCruitment
4 BBK Worldwide
6 Elligo Health Research
8 Science37
TrialX
10
Key Note:

40
4.2.1 IQVIA
Founded in: 1982
HQ: North Carolina, United
States
Type: Public
Revenue: $14,410 Mn
Website: www.iqvia.com
▪ The American multinational corporation IQVIA provides services to
the combined fields of clinical trials and health information
technology.
▪ IQVIA Direct-to-Patient recruiting helps remove barriers that
increase time, cost,
▪ and uncertainty in recruiting efforts by utilizing machine learning
and unprecedented patient data and insight.
Solutions offered by IQVIA
➢ Safety Pharmacovigilance
➢ Medical Information
➢ Commercial Compliance
➢ Clinical Trials
➢ Patient Support
Recent Activity / Press Coverage
IQVIA and (RED) Declare a Groundbreaking Partnership to Support the Strengthening of the Laboratory System
Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science
According to the IQVIA Institute, the use of medicines in the United States grew in 2022 while patient out-of-pocket expenses remained low.

41
4.2.1 IQVIA (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
One of the largest pharmaceutical
distributors in the United States, McKesson
has been a long-standing distribution
partner for IQVIA
Cardinal Health is a Fortune 500 healthcare
services company that provides
pharmaceutical distribution services to
IQVIA
It is one of the largest drugstore chains in
the United States and Europe, and its
extensive network of retail locations and
distribution centers make it an important
distribution partner for IQVIA
A leading healthcare services provider in
Asia, Zuellig Pharma is a distribution
partner for IQVIA in several Asian countries
One of the largest pharmaceutical
wholesalers in Europe, PHOENIX Group
distributes IQVIA's products in several
European countries
IQVIA has been working with SAP, a leading
software company, to develop digital
solutions for its healthcare products
A leading Swiss biotechnology company,
Lonza provides IQVIA with contract
manufacturing services for the production of
its biologics and pharmaceuticals
IQVIA has a strategic partnership with
Microsoft to leverage its cloud computing
and AI technologies in the development of
new healthcare products
Thermo Fisher Scientific is a leading
provider of analytical instruments, reagents,
and laboratory services
GE Healthcare provides IQVIA with
advanced medical imaging and diagnostics
technologies, including CT scanners and
MRI machines
Illustrative

42
Company Name Type
Amount /
Duration
Year Key Pointers
Lilly
Collaboration - March, 2023
▪ IQVIA and Lilly will collaborate on the development of IQVIA
Diagnostics’ Elecsys Amyloid Plasma Panel
▪ Elecsys Amyloid Plasma Panel has demonstrated clinical
performance and is currently undergoing additional investigation
to ensure clinical validation
▪ Once approved, could help healthcare professionals to streamline
the journey to diagnosis for more patients
GenMark Diagnostics
Merger $1.8 Bn March 2021
▪ IQVIA to acquire GenMark Diagnostics for Global$ 24.05 per
share with the expectation to close in the 2nd quarter of 2021
▪ GenMark provides molecular diagnostic tests that are designed to
detect multiple pathogens from a single patient sample
▪ GenMark’s ePlex platform delivers rapid and actionable results so
clinicians can determine the caGlobale of infection and the most
effective treatment, potentially saving lives and alleviating the
healthcare burden
Latest Deals - Mergers and Acquisitions
Illustrative

43
63.3
70.3 70.9
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ According to IQVIA's 2020 financial report,
the company had sales of CHF 58.3 Bn
(Swiss Francs) in 2020
▪ This is equivalent to approximately $63.3
Bn, based on exchange rates at the end of
2020
▪ Company's Pharmaceuticals Division
generated sales of CHF 49.9 Bn in 2020,
while the Diagnostics Division generated
sales of CHF 8.4 Bn
▪ Revenue generated by IQVIA in 2020
reflects the company's continued growth
and success in the healthcare indGlobaltry
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

44
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for
Clinical Trials
Recent Activity / Press Coverage
Illustrative

45
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

46
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

47
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ Please be aware that this sample report is
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

49
5.1 Reimbursement Regulation
The reimbursement scenario in the Global Clinical Trials market is complex and
can vary depending on the specific treatment, setting of care, and insurance
coverage. Here are some key points to consider:
▪ Medicare:
o Medicare is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Medicare covers many Clinical Trials treatments, including
chemotherapy, radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Medicaid:
o Medicaid is a joint federal-state program that provides health insurance
for people with low incomes
o Medicaid coverage for Clinical Trials treatments can vary by state, and
may be subject to limits on the amount and type of treatment covered
▪ Private Insurance:
o Private insurance coverage for Clinical Trials treatments can also vary
widely depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Medicare and Medicaid together provide
health insurance coverage for more than
4 in 10 Americans
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

50
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to Clinical Trials treatments by requiring insurers to
cover certain preventive services, including Clinical Trials screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as Clinical Trials
▪ Reimbursement for New Treatments:
o Reimbursement for new Clinical Trials treatments can be a complex and lengthy process, as insurers and government
programs often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focGlobaling on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

51
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the Global healthcare system, with payers and providers increasingly focGlobaled on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

52
5.2 Reimbursement Process
The reimbursement process in the Global healthcare system can be complex and can vary depending on the type of healthcare
service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

53
5.3 Reimbursement Process
The reimbursement process in the Global healthcare system can be
complex and can vary depending on the type of healthcare service, the
healthcare provider, and the insurance coverage. Here are the general
steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

54
5.4 Reimbursement Process - Medicare
Medicare
Population Covered
▪ 100% population is covered under this scheme
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an
individuals Medicare account
Provider Restrictions/
Selection
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF PlGlobal can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be Globaled to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by Globaling up to $200 per patient per year
from their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs Globaled for cosmetic purposes such as slimming
pills and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for Clinical Trials up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with varioGlobal sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

55
5.5 Reimbursement Process - Medicaid
Medicaid
Population Covered
▪ 38% population is covered under this scheme
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease
Provider Restrictions/
Selection
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF PlGlobal can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be Globaled to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by Globaling up to $200 per patient per year
from their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs Globaled for cosmetic purposes such as slimming
pills and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for Clinical Trials up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with varioGlobal sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the indGlobaltry. We
identify the key growth drivers, opportunities, and restraints that might promote or hinder the future indGlobaltry growth along with an
expansive overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End Globale indGlobaltry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts Globaling the weighted average analysis to derive the
expected market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaGlobaltive primary research with the Key IndGlobaltry Participants (KIPs)
▪ Currency Globaled in the report is the Global dollar (GlobalD), with the market size indicated in GlobalD million/billion (Mn/Bn)
Illustrative

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research
Illustrative

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary
Illustrative

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the indGlobaltry outlook, considering the qualitative and
quantitative indGlobaltry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the indGlobaltry from 2022 to 2030F is provided to enable the stakeholders to capitalize
on the prevailing market opportunities
Extensive analysis of the key segments of the indGlobaltry helps understand the applications and technologies Globaled
globally
Our rigoroGlobal data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the indGlobaltry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
CGlobaltomized
Report
Pricing and purchase
options
Revenue in GlobalD Million/Billion
(Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report CGlobaltomization (3 to 5 working
days) with purchase. We will provide you with
data that is currently not a part of our scope
as a part of cGlobaltomization
Avail cGlobaltomized purchase options to
meet your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focGlobaled market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
bGlobalinesses
www.insights10.com
Lifesciences Market
Research Reports you
can trGlobalt

www.insights10.com
A large database of over 30,000 syndicated
market research reports in Clinical Trial Patient
Recruitment Services and healthcare sector at
global, regional as well as country level. We also
provide cGlobaltomized research reports tailor
made to suit your needs
Get actionable insights to
take informed bGlobaliness
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the bGlobaliness scenario and
the latest trends related to the life sciences
market
Elevate your bGlobaliness
plans with in-depth market
analysis and indGlobaltry
intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's cGlobaltomized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Clinical Trial Patient
Recruitment Services
(Diseases & Drugs)
Digital
Health
Medical
Devices
across varioGlobal categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes Global different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
CGlobaltomized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared Globaling a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter
bGlobaliness and
strategic decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The bGlobaliness decision-making process is no longer as
straightforward as it Globaled to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make bGlobaliness
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences indGlobaltry spanning
across strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav studied
medicine from Gujarat University and also
completed his MBA from IIM-Kozhikode.
Purav started his career with Deloitte
working on strategy consulting
engagements and also co-founded
ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the Global, India, Middle
East and APAC regions. His
primary area of interest is
CGlobaltomer and Market
Strategy, Market Access, and
Digital Health with special
focGlobal on emerging markets
like Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of varioGlobal
stakeholders in pharma & healthcare &
completed several research projects
across life sciences indGlobaltry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences indGlobaltry, Competitor
landscape assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your bGlobaliness
and look forward to serving you.

Global Clinical Trial Patient Recruitment Services Market Analysis Sample Report

Recommended

Recommended

More Related Content

Similar to Global Clinical Trial Patient Recruitment Services Market Analysis Sample Report

Similar to Global Clinical Trial Patient Recruitment Services Market Analysis Sample Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Global Clinical Trial Patient Recruitment Services Market Analysis Sample Report